Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$480.26 USD

480.26
1,436,491

+3.18 (0.67%)

Updated Aug 15, 2025 03:59 PM ET

After-Market: $480.30 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

5 Defensive Stocks for Stable Returns Amid Recent Volatility

by Nalak Das

We have narrowed our search to five stocks from defensive sectors. These are: JNJ, PEP, ISRG, KMB, ATO.

Zacks Equity Research

Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Zacks Equity Research

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

by Zacks Equity Research

QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.

Zacks Equity Research

Here's Why You Should Invest in Medtronic (MDT) Stock Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

Zacks Equity Research

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

by Zacks Equity Research

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.

Zacks Equity Research

National Vision (EYE) Gains From Store Openings Amid Cost Woes

by Zacks Equity Research

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips

by Zacks Equity Research

Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.

Zacks Equity Research

Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

by Zacks Equity Research

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

Zacks Equity Research

ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.

Zacks Equity Research

AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.

Zacks Equity Research

DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up

by Zacks Equity Research

Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.

Zacks Equity Research

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

by Zacks Equity Research

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up

by Zacks Equity Research

Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Zacks Equity Research

Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Zacks Equity Research

Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Zacks Equity Research

Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit

by Zacks Equity Research

Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.

Zacks Equity Research

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

Zacks Equity Research

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

Zacks Equity Research

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Zacks Equity Research

Envista (NVST) Q2 Earnings Top Estimates, Margins Expands

by Zacks Equity Research

Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.